ArticleScientific reports2016
Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 63 citations in OpenAlex.
- Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data.Cancer research · 2019Trial
- Overcoming vascular niche-mediated TKI resistance in acute myeloid leukemia through miR-126 inhibition.NPJ systems biology and applications · 2026Article
- Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer.Molecular cancer research : MCR · 2025Article
- Exploring bone-tumor interactions through 3DJournal of bone oncology · 2025Review
- Mechanobiological cues to bone cells during early metastasis drive later osteolysis: A computational mechanoregulation framework prediction.Mechanobiology in medicine · 2025Article
- Evolutionary rescue model informs strategies for driving cancer cell populations to extinction.bioRxiv : the preprint server for biology · 2025Article
- The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease.Nature communications · 2024Article
- Development and Validation of a Clinic Machine Learning Classifier for the Prediction of Risk Stratifications of Prostate Cancer Bone Metastasis Progression to Castration Resistance.International journal of general medicine · 2024Article
- Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TβRI expression.Cancer letters · 2023Article
- γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer.Science advances · 2023Article
- Data integration between clinical research and patient care: A framework for context-depending data sharing and in silico predictions.PLOS digital health · 2023Article
- A combined experimental-computational approach uncovers a role for the Golgi matrix protein Giantin in breast cancer progression.PLoS computational biology · 2023Article
- A multi-layered hybrid model for cancer cell invasion.Medical & biological engineering & computing · 2022Article
- Antigen receptor therapy in bone metastasis via optimal control for different human life stages.Journal of mathematical biology · 2021Article
- Emerging roles for myeloid immune cells in bone metastasis.Cancer metastasis reviews · 2021Review
- Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer.Nature communications · 2021Article
- Prostate cancer-derived MMP-3 controls intrinsic cell growth and extrinsic angiogenesis.Neoplasia (New York, N.Y.) · 2020Article
- An agent-based model of prostate Cancer bone metastasis progression and response to Radium223.BMC cancer · 2020Article
- Modeling the Human Bone-Tumor Niche: Reducing and Replacing the Need for Animal Data.JBMR plus · 2020Review
- Tumor cell-organized fibronectin maintenance of a dormant breast cancer population.Science advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The ability to rapidly assess the efficacy of therapeutic strategies for incurable bone metastatic prostate cancer is an urgent need. Pre-clinical in vivo models are limited in their ability to define the temporal effects of therapies on simultaneous multicellular interactions in the cancer-bone microenvironment. Integrating biological and computational modeling approaches can overcome this limitation. Here, we generated a biologically driven discrete hybrid cellular automaton (HCA) model of bone metastatic prostate cancer to identify the optimal therapeutic window for putative targeted therapies. As proof of principle, we focused on TGFβ because of its known pleiotropic cellular effects. HCA simulations predict an optimal effect for TGFβ inhibition in a pre-metastatic setting with quantitative outputs indicating a significant impact on prostate cancer cell viability, osteoclast formation and osteoblast differentiation. In silico predictions were validated in vivo with models of bone metastatic prostate cancer (PAIII and C4-2B). Analysis of human bone metastatic prostate cancer specimens reveals heterogeneous cancer cell use of TGFβ. Patient specific information was seeded into the HCA model to predict the effect of TGFβ inhibitor treatment on disease evolution. Collectively, we demonstrate how an integrated computational/biological approach can rapidly optimize the efficacy of potential targeted therapies on bone metastatic prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.